Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, Cacho Lavin D, Limon ML, Sauri T, Lopez F, Visa L, Granja M, Martinez Lago N, Arrazubi V, Vidal Tocino R, Hernandez R, Aguado G, Cano JM, Martin Carnicero A, Mangas M, Pimentel P, Fernandez Montes A, Macias Declara I, Longo F, Ramchandani A, Martin Richard M, Hurtado A, Azkarate A, Hernandez Perez C, Serrano R, Gallego J; AGAMENON-SEOM study group. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Ther Adv Med Oncol. 2021 Jun 17;13:17588359211019672. doi: 10.1177/17588359211019672. eCollection 2021. PubMed PMID: 34211587; PubMed Central PMCID: PMC8216357.
AÑO: 2021; IF: 5.485
34211587
Martin I, Villamon E, Abellan R, Calasanz MJ, Irigoyen A, Sanz G, Such E, Mora E, Gutierrez M, Collado R, Garcia-Serra R, Vara M, Blanco ML, Oiartzabal I, Alvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil A, Diez-Campelo M, Solano C, Tormo M; Spanish Group of Myelodysplastic Syndromes (GESMD). Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Br J Haematol. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. Epub 2021 Jul 22. PubMed PMID: 34296432.
AÑO: 2021; IF: 8.615
34296432
Puig N, Hernandez MT, Rosinol L, Gonzalez E, de Arriba F, Oriol A, Gonzalez-Calle V, Escalante F, de la Rubia J, Gironella M, Rios R, Garcia-Sanchez R, Arguinano JM, Alegre A, Martin J, Gutierrez NC, Calasanz MJ, Martin ML, Couto MDC, Casanova M, Arnao M, Perez-Persona E, Garzon S, Gonzalez MS, Martin-Sanchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortes-Rodriguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Blade J, Niesvizky R, Mateos MV. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer J. 2021 May 21;11(5):101. doi: 10.1038/s41408-021-00490-8. PubMed PMID: 34021118; PubMed Central PMCID: PMC8139975.
AÑO: 2021; IF: 9.812
34021118
Novelli S, Bento L, Garcia I, Prieto L, Lopez L, Gutierrez G, Hernani R, Perez A, Esquirol A, Solano C, Bastos M, Dorado N, Rodriguez N, Rodriguez G, Pinana JL, Montoro J, Herrera P, Luna A, Parody R, Martin C, Garcia E, Lopez O, Heras I, Zanabili J, Moraleda JM, Yanez L, Gutierrez A, Zudaire T, Cordoba R, Varela R, Ferra C, Martinez J, Martinez C, Gonzalez-Barca E, Martino R, Caballero D; GELTAMO and GETH. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplant Cell Ther. 2021 Jun;27(6):493.e1-493.e8. doi: 10.1016/j.jtct.2021.03.014. Epub 2021 Mar 15. PubMed PMID: 33857447.
AÑO: 2021; IF: 0.0
33857447
Megy K, Downes K, Morel-Kopp MC, Bastida JM, Brooks S, Bury L, Leinoe E, Gomez K, Morgan NV, Othman M, Ouwehand WH, Perez Botero J, Rivera J, Schulze H, Tregouet DA, Freson K. GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis. J Thromb Haemost. 2021 Oct;19(10):2612-2617. doi: 10.1111/jth.15459. Epub 2021 Aug 5. Erratum In: J Thromb Haemost. 2023 Apr;21(4):1067. PubMed PMID: 34355501; PubMed Central PMCID: PMC9291976.
AÑO: 2021; IF: 16.036
34355501
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL